Arnaud Flamand

Arnaud advises local and international (public and privately held) companies, investment banks and institutions, as well as private equity funds on all aspects related to corporate finance, with a focus on capital market, M&A, private equity and funds structuring.

Arnaud advised clients in wide a range of capital market operations, as well as M&A operations. Arnaud also advised clients on the incorporation of alternative investment funds under the form of partnerships, structuration of all internal documentation and further capital calls and raising (including equalizations).

• Advised MDxHealth on the initial public offering on the Nasdaq.
• Advised Mithra Pharmaceuticals on the offering of its EUR 125 million senior unsecured convertible bonds.
• Advised Mithra Pharmaceuticals on the conclusion of a EUR 100 million equity financing agreement (under ISDA rules) with Goldman Sachs International.
• Advised Mithra Pharmaceuticals on the conclusion of a senior secured convertible facilities agreement with Highbridge and Whitebox in an amount of up to EUR 100 million.
• Advised Nyxoah on the initial public offering on Euronext Brussels (Syndicate's counsel).
• Advised Mayfair Equity Partners on the acquisition of the Jonckers Group.
• Advised a European group on the acquisition of a non-listed Belgian company active in the food industry.
• Advised another European group on the acquisition of two Belgian companies.
• Advised a Belgian group on the acquisition and restructuring of a large retail-shopping group.